Dyne CMO granted RSUs and options

Dyne Therapeutics Chief Medical Officer Kerr Douglas reported new equity awards in the company.

Rhea-AI Filing Summary

Dyne Therapeutics Chief Medical Officer Kerr Douglas reported new equity awards in the company. On February 12, 2026, Douglas received 85,000 shares of Common Stock in the form of restricted stock units, bringing direct beneficial ownership of Common Stock to 172,510 shares, including 156,625 unvested RSUs.

Douglas was also granted a stock option for 130,000 shares of Common Stock at an exercise price of $16 per share. The option is scheduled to vest in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.

Insider Trade Summary

Grant/Award: 215,000 shares

Grant/Award 2 txns

Insider Kerr Douglas

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	130,000	$0.00	$0.00
Grant/Award	Common Stock	85,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 130,000 contracts (Direct); Common Stock — 172,510 shares (Direct)

Footnotes (3)

1. F1. Consists of shares of Common Stock issuable under 85,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.
2. F2. Includes 156,625 unvested RSUs.
3. F3. This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.

FAQ

What insider transaction did Dyne Therapeutics (DYN) report for Kerr Douglas?

Dyne Therapeutics reported that Chief Medical Officer Kerr Douglas received equity awards on February 12, 2026. These included 85,000 restricted stock units in Common Stock and a stock option covering 130,000 shares, both structured as multi-year vesting compensation.

How many Dyne Therapeutics (DYN) shares does Kerr Douglas beneficially own after this Form 4?

After the reported awards, Kerr Douglas beneficially owns 172,510 shares of Dyne Therapeutics Common Stock directly. This figure includes 156,625 unvested restricted stock units, which represent shares that may be delivered as they vest over time.

What are the terms of Kerr Douglas’s new stock option in Dyne Therapeutics (DYN)?

Kerr Douglas received a stock option for 130,000 Dyne Therapeutics Common Stock shares at a $16 exercise price. The option was granted on February 12, 2026 and is scheduled to vest in equal monthly installments over four years, through February 12, 2030.

How do the new restricted stock units for Dyne Therapeutics (DYN) vest?

The 85,000 restricted stock units granted to Kerr Douglas each represent one share of Common Stock. They are scheduled to vest in equal quarterly installments over four years, with the first vesting installment occurring on May 12, 2026, subject to continued service conditions.

Is Kerr Douglas’s ownership in Dyne Therapeutics (DYN) direct or through another entity?

The Form 4 indicates that Kerr Douglas’s reported holdings in Dyne Therapeutics Common Stock and stock options are held as direct ownership. There is no footnote stating that the shares are controlled by a separate trust, partnership, or other indirect ownership entity.

Does this Dyne Therapeutics (DYN) Form 4 reflect a purchase or a grant to Kerr Douglas?

The Form 4 reflects equity grants to Kerr Douglas rather than open-market purchases. Both the 85,000 restricted stock units and the 130,000-share stock option are coded as awards or other acquisitions, with a reported price of $0.00 per share for the grant events themselves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kerr Douglas

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		85,000(1)	A	$0	172,510(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$16	02/12/2026		A		130,000		(3)	02/11/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. Consists of shares of Common Stock issuable under 85,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.

2. Includes 156,625 unvested RSUs.

3. This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.

	/s/ Ron Caponigro, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.